Astellas Value Creation

Towards the Realization of Our VISION

Astellas’ raison d’être is to “contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.” Based on this, we aim to ”be on the forefront of healthcare change to turn innovative science into value for patients.” This is Astellas’ VISION.

For the realization of our VISION, we announced Corporate Strategic Plan 2021 (“CSP2021”) in May 2021. While inheriting the basic strategy of Corporate Strategic Plan 2018, the company set four strategic goals with the intention of evolving and developing each strategic goal.

To address Strategic Goal 1 “Enable patients to achieve better outcomes,” we will seek to maximize the value of strategic products.

For the achievement of Strategic Goal 2 “Translate innovative science into proven VALUE,” Astellas will enhance its pipeline value by giving priority to investing management resources into multiple programs, created from the Focus Area approach.

For Strategic Goal 3 “Advance the Rx+® business,” Astellas aims to commercialize multiple projects during the CSP2021 period.

In addition, we set “Deepen our engagement to sustainability” as a brand new, fourth Strategic Goal under CSP2021.

By firmly committing to these Strategic Goals, we will make steady progress towards the realization of our VISION.


VISION arrow



Corporate Strategic Plan 2021 arrow

Corporate Strategic Plan 2021

Business Review

Creation of VALUE for patients

Realization of our VISION

*Adapted from “What Is Value in Health Care?” Porter, M.E. (2010). New England Journal of Medicine